Latus Bio Achieves Major Regulatory Milestone with IND Clearance and Triple FDA Designations for LTS-101 in CLN2 Disease Latus Bio, Inc., a clinical-stage biotechnology company at the forefront of adeno-associated…
AdvanCell Launches Pivotal Phase 2 Expansion Trial of ADVC001, a First-in-Class Targeted Alpha Therapy for Metastatic Prostate Cancer AdvanCell, a clinical-stage radiopharmaceutical company at the forefront of developing next-generation targeted…
Samsung Bioepis Launches Denosumab Biosimilars OBODENCE™ and XBRYK™ in Europe to Improve Access and Patient Outcomes Samsung Bioepis Co., Ltd., a global biopharmaceutical company recognized for its innovative work in…
Janux Therapeutics Reports Encouraging Interim Phase 1 Data for JANX007 in mCRPC, Highlighting Strong Efficacy and Manageable Safety Profile Janux Therapeutics, Inc. a clinical-stage biopharmaceutical company pioneering novel immunotherapies through…
AltPep Corporation Presents New Preclinical Data Demonstrating SOBIN-AD Peptide Improves Cognition in Early and Symptomatic Alzheimer’s Disease Models at CTAD 2025 AltPep Corporation, a privately held biotechnology company dedicated to…
Cellares Appoints Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion and Drive Cell Therapy Access Cellares, the pioneering Integrated Development and Manufacturing Organization (IDMO) transforming the cell…
Vistagen Appoints Nick Tressler as Chief Financial Officer, Strengthening Leadership Team Amid Growth and Clinical Milestones Vistagen Therapeutics, Inc. a late clinical-stage biopharmaceutical company focused on pioneering neuroscience innovations through…
Octave Bioscience Partners with Quest Diagnostics to Expand Nationwide Access to MSDA Test Octave Bioscience, a commercial-stage precision care company at the forefront of redefining disease management in multiple sclerosis…
Omeros Corporation Announces Completion of Asset Purchase and License Agreement with Novo Nordisk for Zaltenibart a Late-Stage MASP-3 Inhibitor Omeros Corporation today announced the successful closing of its previously disclosed…
Mirum Pharmaceuticals Enrolls First Participant in BLOOM Phase 2 Study Evaluating MRM-3379 for Fragile X Syndrome Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and delivering innovative therapies for…
Incyte Announces Appointment of Richard Hoffman as Executive Vice President and General Counsel Incyte today announced that Richard Hoffman has officially assumed the role of Executive Vice President and General…
Circle Pharma Appoints Anne E. Borgman, M.D., as Chief Medical Officer, Strengthening Leadership Team to Advance Next-Generation Macrocycle Oncology Pipeline Circle Pharma, Inc., a clinical-stage biopharmaceutical company advancing a new…
